Abciximab may serve as a successful rescue treatment for acute ischemic stroke refractory to standard thrombolysis and angioplasty.
May support abciximab rescue in refractory stroke; hypothesis-generating and requires prospective trials before practice change.
In acute ischemic stroke, reocclusion after an initially successful thrombolysis treatment can occur and is associated with increased morbidity and mortality. The authors present the successful use of abciximab, a platelet glycoprotein IIb/IIIa receptor inhibitor, in a patient with a thrombotic occlusion of the proximal middle cerebral artery, which was refractory to combined IV and intra-arterial thrombolysis and percutaneous intracranial balloon angioplasty.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: